

Contents

WHO Expert Committee on Drug Dependence	v
Abbreviations	viii
Introduction	1
1. Work of international bodies concerned with controlled substances	4
1.1 Update from the International Narcotics Control Board	4
1.2 Update from the United Nations Office on Drugs and Crime	4
1.3 Update from Management of Substance Abuse Unit, WHO	5
1.4 Update from Essential Medicines and Health Products, WHO	6
2. Criteria for assessing new psychoactive substances	8
3. Terminology	9
4. Follow-up on recommendations made by the ECDD at its thirty-sixth meeting	10
4.1 Mephedrone	10
4.2 Ketamine (INN)	10
4.3 AH-7921	11
4.4 Gamma-butyrolactone (GBL)	11
4.5 1,4-Butanediol (1,4-BD)	12
4.6 25B-NBOMe	12
4.7 25C-NBOMe	12
4.8 25I-NBOMe	13
4.9 <i>N</i> -Benzylpiperazine (BZP)	13
4.10 JWH-018	13
4.11 AM-2201	14
4.12 3,4-Methylenedioxypropylamphetamine (MDPV)	14
4.13 Methylone (BK-MDMA)	15
5. Critical review of psychoactive substances	16
5.1 MT-45	16
5.2 Acetylfentanyl	18
5.3 α -Pyrrolidinovalerophenone (α -PVP)	20
5.4 4-Fluoroamphetamine (4-FA)	21
5.5 <i>para</i> -Methyl-4-methylaminorex (4,4'-DMAR)	22
5.6 <i>para</i> -Methoxymethylamphetamine (PMMA)	24
5.7 Methoxetamine (MXE)	25
6. Pre-review of psychoactive substances	28
6.1 Etizolam (INN)	28
6.2 Phenazepam	30

7. Updates	32
7.1 Ketamine (INN)	32
7.2 Cannabis and cannabis resin	32
8. Future agenda items	33
Acknowledgements	34
References	34

